Teva Pharmaceuticals Industries Ltd. (NYSE:TEVA) and Sanofi SA (NASDAQ:SNY) presented new, detailed results from the RELIEVE ...

Regulatory ApprovalFormycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE® 25.02.2025 / 06:30 CET/CESTThe issuer is solely ...

EQS-News: Formycon AG / Key word (s): Regulatory Approval Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE® ...

The Business Research Company Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.

Sanofi has shared a deeper dive into its 469 million euro ($491 million) bowel disease bet, publishing phase 2 data that ...

Bank Leumi (TASE: LUMI) led the market today, falling 1.02% on the day's biggest trading turnover. Bank Hapoalim (TASE: POLI) fell 1.37%, Mizrahi Tefahot Bank fell 0.53% and Israel Discount Bank (TASE ...

Coming in first on the list of Top 25 Pharma Companies US Rx is AbbVie, reaching $41,857m in US Rx revenue in 2023 and ...

Revenues in the biopharma industry continued to boom in the fourth quarter of last year, following a pattern seen ...

Sanofi & Teva's IBD drug duvakitug shows promise in Phase 2b with €1B sales potential by 2032, faces competition from Roivant ...

The global penicillin drug market size was valued at US$ 8.71 billion in 2023 and is projected to reach US$ 12.08 billion by 2032, registering a CAGR of 3.7% during the forecast period from 2024 to ...